Serge Picaud
Directeur Technique/Scientifique/R&D chez Institut de la Vision
Profil
Serge Picaud is the founder of Pixium Vision SA founded in 2011 and Gensight Biologics SA founded in 2012.
Dr. Picaud is also the founder of Fovea Pharmaceuticals SA. Currently, he holds the position of Director-Research at Institut de la Vision.
Postes actifs de Serge Picaud
| Sociétés | Poste | Début |
|---|---|---|
Institut de la Vision
 Institut de la Vision Medical/Nursing ServicesHealth Services Institut de la Vision is a research center located in Paris, France that focuses on discovering, developing, and testing treatments and technological innovations for eye diseases. The French company's objective is to improve the autonomy and quality of life of patients. The private company was founded by José-Alain Sahel. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Serge Picaud
| Sociétés | Poste | Fin |
|---|---|---|
Fovea Pharmaceuticals SA
 Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Fondateur | - |
| GENSIGHT BIOLOGICS S.A. | Fondateur | - |
| PIXIUM VISION | Fondateur | - |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| PIXIUM VISION | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Institut de la Vision
Institut de la Vision Medical/Nursing ServicesHealth Services Institut de la Vision is a research center located in Paris, France that focuses on discovering, developing, and testing treatments and technological innovations for eye diseases. The French company's objective is to improve the autonomy and quality of life of patients. The private company was founded by José-Alain Sahel. | Health Services |
Fovea Pharmaceuticals SA
Fovea Pharmaceuticals SA Pharmaceuticals: MajorHealth Technology Fovea operates within the ophthalmic pharmaceutical market, which is expected to grow at a double-digit annual rate during the years to come. This growth is likely to be driven by new technologies and products, premium pricing facing no significant reimbursement issues, favorable trends (aging of the population, diabetes epidemiology and environmental factors) and dramatic expansion into the large and mostly untapped market for retinal degenerative diseases. With a limited number of players, the ophthalmology market has proved recently to be an early adopter of innovations, allowing new players to gain visibility very rapidly. During the last three years, Fovea has implemented this strategy, by acquiring products from large pharmaceutical or biotech companies and is actively developing them in four different indications. It has also integrated a unique drug discovery platform and has been able to identify one preclinical candidate and several interesting new targets. | Health Technology |
